A5000525925- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Venous Thromboembolism Diagnosis and Management
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Cancer survivorship and care
- Cardiac tumors and thrombi
- Neuroendocrine Tumor Research Advances
- Central Venous Catheters and Hemodialysis
- Breast Lesions and Carcinomas
- Genetic factors in colorectal cancer
- Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Palliative Care and End-of-Life Issues
- Neuroblastoma Research and Treatments
- Nutrition and Health in Aging
- Acute Ischemic Stroke Management
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
Hospital de Basurto
2013-2025
GEICAM – Spanish Breast Cancer Group
2009-2025
Roche (Switzerland)
2021
Osakidetza
2013-2017
Hospital Clínico Universitario Virgen de la Victoria
2009
Universitat de València
2009
Instituto de Investigación Sanitaria La Fe
2009
Hospital Universitario Reina Sofía
2009
Purpose To confirm the efficacy of a risk-adapted treatment approach for patients with clinical stage I seminoma. The aim was to reduce both risk relapse and proportion receiving adjuvant chemotherapy while maintaining high cure rate. Patients Methods From 2004 2008, 227 were included after orchiectomy in multicenter study. Eighty-four (37%) presented no local factors, 44 (19%) had tumors larger than 4 cm, 25 (11%) rete testis involvement, 74 (33%) criteria. Only latter group received two...
In many cancers, the expression of immunomodulatory ligands leads to immunoevasion, as exemplified by interaction PD-L1 with PD-1 on tumor-infiltrating lymphocytes. Profound advances in cancer treatments have come advent immunotherapies directed at blocking these immuno-suppressive ligand-receptor interactions. However, although there has been success use immune checkpoint interventions, correct patient stratification for therapies challenging.To address this issue stratification, we...
<b><i>Introduction:</i></b> Pancreatic neuroendocrine neoplasms (PNENs) are uncommon with a wide spectrum of clinical behavior. The objective this study was to assess in large cohort patients the relative impact prognostic factors on survival. <b><i>Methods:</i></b> From June 2001 through October 2010, 1,271 were prospectively registered online (www.getne.org) at Spanish National Cancer Registry for Gastroenteropancreatic Neuroendocrine Tumors...
Abstract Breast cancer is a heterogeneous disease comprising variety of entities with various genetic backgrounds. Estrogen receptor-positive, human epidermal growth factor receptor 2-negative tumors typically have favorable outcome; however, some patients eventually relapse, which suggests heterogeneity within this category. In the present study, we used proteomics and miRNA profiling techniques to characterize set 102 either estrogen receptor-positive (ER+)/progesterone (PR+) or...
Abstract Background Identifying high-risk of late recurrence (beyond 10 years) in patients with hormone receptor-positive HER2-negative early breast cancer (EBC) is crucial. The Clinical Treatment Score post-5 years (CTS5) score assesses risk after 5 endocrine therapy (ET). This study validated CTS5 as a prognostic tool for by examining its association Distant Recurrence-Free Survival using GEICAM data and evaluating model calibration. Patients methods We retrospectively analyzed 5739 EBC...
Pancreatic carcinoma is one of the tumors associated with a higher risk for thromboembolic events, incidence rates ranging from 5% to 41% in previous retrospective series.We conducted study eleven Spanish hospitals that included 666 patients diagnosed pancreatic (any stage) between 2008 and 2011 treated chemotherapy. The main objective was evaluate venous events (VTE) this population, as well potential factors thrombosis. impact VTE on mortality also assessed.With median follow-up 9.3...
Purpose: The 21-gene recurrence score (RS) is a genomic test developed as prognostic and predictive tool to improve the treatment decision making in cases of estrogen receptor-positive human epidermal growth factor receptor 2-negative early-stage breast cancer. This study examined clinical economic impact its use 4 Basque Country university hospitals. Methods: Taking into consideration RS result, we recorded recommended initial systemic adjuvant therapy (endocrine with or without...
Estimating the risk of late distant recurrence (DR) is an important goal for management hormone receptor-positive (HR+) early breast cancer (EBC) patients (pts) after 5 years endocrine treatment (ET) without recurrence. The Clinical Treatment Score post–5 (CTS5) tool was developed to estimate residual Distant Recurrence ET (Dowsett 2018). CTS5 a continuous score based on 4 clinical variables (number positive nodes, tumor size, grade, and age) which distributes HR+/human epidermal growth...
e20658 Background: Splanchnic vein thrombosis (SVT) is a common complication in exocrine pancreatic cancer (EPC) receiving chemotherapy ambulatory setting. However it´s true incidence and prognosis remains uncertain. So far, only few studies have addressed the outcome of patients with EPC SVT. Methods: We performed retrospective chart review to determine SVT attended ten hospitals Cancer & Thrombosis Working Group Spanish Society Medical Oncology (SEOM). 626 consecutive who were diagnosed...
Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development fatal pulmonary embolisms (PE). Little known about factors involved clot stability, with angiogenesis possibly being implicated. The database TESEO prospective registry that recruits patients VTE 41 Spanish hospitals. Independent validation was conducted cohort Caravaggio trial. objective to evaluate association between exposure antiangiogenic therapies and PE/VTE...
Patients with cancer present a higher risk of rethrombosis and bleeding secondary to anticoagulant treatment than individuals without cancer. Given the lack specific clinical trials, decision regarding optimal duration must consider multiple factors, including sex. The current study used data from international, prospective TESEO Registry that includes consecutive patients diagnosed cancer-associated thrombosis (CAT). Between July 2018 December 2022, 2,823 were included in Registry, 1,351...
Trastuzumab deruxtecan has shown efficacy in ABC pts with low HER2 positivity by immunohistochemistry (IHC) and a negative situ hybridization (ISH), termed H-Low (HER2 1+, or 2+ ISH). A better understanding of this heterogeneous group is needed. This analysis from RegistEM study (NCT02819882) compares characteristics outcomes H-0 diagnosed Jan-16 to Dec-19. With cut-off 14-Nov-22, an ongoing database, 1232 HER2- were included, 713 519 (IHC1+ 54%, IHC2+ ISH- 46%). Pts split 4 groups based on...
e12016 Background: El Álamo project is a retrospective analysis of 26833 patients (pts) diagnosed breast cancer (BC) between 1990 and 2001 across 43 the main Spanish hospitals. Patterns BC presentation, treatment survival in women population were analyzed. Methods: Three cohorts analyzed: I (AI) with 4,532 pts 1993; II (AII) 10,791 1994 1997; III (AIII) 11,277 1998 2001. Data collected by end year 2000, 2003 2007 for AI, AII AIII respectively. 468 items per pt recorded, including...
We report the case of a 19-year-old woman 33 weeks pregnant who presented painful mass progressive growth in neck, having also dysphonia and dyspnea. Physical examination revealed primary laryngeal tumor. A neuroendocrine small-cell carcinoma was diagnosed after histopathology, immunohistochemistry genetic studies. Chemo-radiotherapy with cisplatin-etoposide schedule administered. Despite obtaining complete response, patient relapsed finally survived 35 months successive cisplatin-based...
e13056 Background: VTE is a common complication in HGG; however, it´s incidence remain uncertain. KS the only validated predictive model to gauge cancer patient´s risk for developing VTE. Methods: The aim of this study analyze and ambulatory patients (pts) with HGG receiving chemotherapy. We performed retrospective review 10 hospitals Cancer Thrombosis Working Group Spanish Society Medical Oncology (SEOM). A total 469 consecutive from January 2008 through December 2011 were included...